Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rigontec Buy Adds RNA Tech To Merck & Co IO Portfolio

Executive Summary

Merck & Co. adds to its immuno-oncology pipeline with the acquisition of Rigontec for an upfront payment of €115m, with the three-year-old company offering Merck a unique approach to immunotherapy and a lead candidate currently in Phase I/II trials, the first of its kind in human studies.

Advertisement

Related Content

Boehringer Ingelheim Is Getting Bets In Early In IO Space
Boehringer Ingelheim Expands Oncolytic Virus Efforts With ViraTherapeutics Buy
Boehringer's Expanded Venture Fund: Innovation First, Returns Second
Biopharma Quarterly Dealmaking Statistics, Q3 2017
Start-Up Quarterly Statistics: Fundraising Fell, But Deal-Making Rose In Q3

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099436

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel